SCHEMBL20004011

SCHEMBL20004011

N#Cc1cccc(-c2ccc3nccn3c2)c1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 2/20 0.60
GRM5 P41594 4/20 0.53
DYRK1A Q13627 2/20 0.53
CLK4 Q9HAZ1 1/20 0.50
PDE4A P27815 1/20 0.47
PDE3A Q14432 1/20 0.47
CYP3A4 P08684 1/20 0.46
HPGD P15428 1/20 0.46
NFKB1 P19838 1/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TGFBR1 P36897 2/20 0.45
TGFBR2 P37173 1/20 0.45
TRIM33 Q9UPN9 1/20 0.45
EGLN2 Q96KS0 1/20 0.45
NAMPT P43490 1/20 0.43
MAP4K4 O95819 1/20 0.43
FAAH O00519 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15638528 0.86 TGFBR1 (0.55) ALDH1A3GRM5DYRK1ACLK4PDE4A
SCHEMBL20004003 0.83 DYRK1A (0.65) ALDH1A3DYRK1APDE4APDE3ACYP3A4
SCHEMBL25367402 0.81 DYRK1A (0.44) ALDH1A3GRM5DYRK1ACLK4PDE4A
SCHEMBL30520046 0.81 DYRK1A (0.44) ALDH1A3GRM5DYRK1ACLK4PDE4A
SCHEMBL20600623 0.79 TGFBR1 (0.44) ALDH1A3DYRK1APDE4APDE3ATGFBR1
SCHEMBL30186375 0.78 DYRK1A (0.57) DYRK1ACYP3A4TGFBR1TGFBR2FAAH
SCHEMBL1832251 0.78 DYRK1A (0.57) DYRK1ATGFBR1TGFBR2FAAH
SCHEMBL13680666 0.78 TGFBR1 (0.68) ALDH1A3DYRK1APDE4APDE3ACYP3A4
SCHEMBL14320819 0.78 DYRK1A (0.63) DYRK1ACYP3A4TGFBR1TGFBR2MAP4K4
SCHEMBL30007309 0.78 DYRK1A (0.63) DYRK1ACYP3A4TGFBR1TGFBR2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3943490-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2022-01-26 EP disclosed
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-20 US disclosed
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-06 US disclosed
EP-3842427-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2021-06-30 EP disclosed
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2020-06-23 US disclosed
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-06-11 US disclosed
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-10-24 US disclosed
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-19 US disclosed
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-05 US disclosed
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors Missions Therapeutics Limited (GB) 2019-07-09 US disclosed
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 ALDH1A3 2607/4885GRM5 4169/4885DYRK1A 3140/4885
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 ALDH1A3 2624/4885GRM5 3586/4885DYRK1A 2639/4885
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 ALDH1A3 2624/4885GRM5 3586/4885DYRK1A 2639/4885
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 ALDH1A3 2509/4885GRM5 3481/4885DYRK1A 2631/4885
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 ALDH1A3 2607/4885GRM5 4169/4885DYRK1A 3140/4885
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 ALDH1A3 2624/4885GRM5 3586/4885DYRK1A 2639/4885
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 ALDH1A3 2624/4885GRM5 3586/4885DYRK1A 2639/4885
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 ALDH1A3 2624/4885GRM5 3586/4885DYRK1A 2639/4885
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 ALDH1A3 2624/4885GRM5 3586/4885DYRK1A 2639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.